Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Social Stream
CAN-FITE BIOPHARMA LTD (CANF) Price Targets From Analysts
Use the tables below to see what analysts covering CAN-FITE BIOPHARMA LTD think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-09-13 | 2 | $50 | $50 | $50 | $2.06 | 2327.18% |
| 2022-11-29 | 2 | $5 | $5 | $5 | $2.06 | 142.72% |
| 2022-12-12 | 2 | $8 | $5 | $6.5 | $2.06 | 215.53% |
| 2023-01-27 | 2 | $34 | $34 | $34 | $2.06 | 1550.49% |
| 2023-06-02 | 2 | $34 | $6 | $20 | $2.06 | 870.87% |
| 2023-08-31 | 2 | $34 | $6 | $17.333 | $2.06 | 741.41% |
| 2023-11-03 | 2 | $18 | $6 | $12 | $2.06 | 482.52% |
The Trend in the Analyst Price Target
CANF's average price target has moved up $7 over the prior 16 months.
CANF reports an average of 618.09% for its upside potential over the past 40 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-01 | 2 | 34 | 6 | 20 | 1.750 | 1042.86% |
| 2023-05-30 | 2 | 34 | 6 | 20 | 2.465 | 711.36% |
| 2023-06-02 | 2 | 34 | 6 | 20 | 2.790 | 616.85% |
| 2023-10-24 | 2 | 18 | 6 | 12 | 1.950 | 515.38% |
| 2023-11-03 | 2 | 18 | 6 | 12 | 2.175 | 451.72% |
CANF Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 2 | 0 | 0 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
CANF's average broker recommendation rating improved by 0 over the prior 48 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CANF as an investment opportunity.
- CAN-FITE BIOPHARMA LTD's number of analysts covering the stock is greater than 19.81% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, CAN-FITE BIOPHARMA LTD's upside potential (average analyst target price relative to current price) is higher than 656.03% of them.
- To contextualize these metrics, consider that out of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's variance in analysts' estimates is lower than -247.34% of them.
- To contextualize these metrics, consider that out of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's average analyst price target is greater than 443.53% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to CAN-FITE BIOPHARMA LTD are BLRX, GLMD, and EDSA.
View All Top Stocks by Price Target
Is CANF a Buy, Hold or Sell? See the POWR Ratings now!